Merck’s Keytruda Approved for Advanced Melanoma Treatment
Advanced Melanoma patients are now able to take a powerful new immuno-cology drug from Merck called Keytruda.
Stivarga Approved for GIST in EU
The European Commission recently announced that Stivarga (regorafenib) from Bayer has been approved in the European Union (EU) as a third line treatment for GIST.
Lancet Oncology Publishes List of Drugs to Avoid for Patients on Tyrosine Kinase Inhibitors
Lancet Oncology, a comprehensive overview of known or suspected drug-drug interactions between tyrosine-kinase inhibitors (Gleevec, Sutent, Stivarga) prescribed for GIST.
FDA Supports Patient Perspective to Promote Pharmaceutical Innovation
Dr. Janet Woodcock, director of the Center for Drug Evaluation and Research spoke to the House of Representatives about patient perspective.
FDA Receives Treatment Guidance from Patient Advocates
Patient advocacy is a vital component in assuring that roadblocks to optimal treatment do not prevent cancer patients from obtaining the help they deserve. Recently, a group from Parent Project Muscular Dystrophy presented the FDA [...]
Personalized Medicine: Paradigm of the Future for Cancer Treatment
Personalized or targeted medicine is the paradigm of the future: treatment options customized for individual patients.
Promising future treatments for GIST after Tyrosine Kinase Inhibitors
A recent study by Margaret von Mehren, MD and Dr. Natthapol Songdej of Fox Chase Cancer Center discusses the role of new treatments for GIST
Cancer Treatment – The Emotional and Economic Costs
There are multiple costs associated with cancer treatment. The emotional cost of cancer is obvious: fear and anxiety become constant companions. The economic cost is less apparent initially, as the patient and their support team [...]
Trial Finds that Adjuvant Imatinib Impacts Recurrence-Free Survival
A recent clinical trial found that 1 year of adjuvant imatinib was able to increase recurrence-free survival. Keep reading to learn more.
Imatinib Rechallenge Impacts GIST Survival Rate
A recent nonrandomized study has shown that imatinib rechallenge impacted the survival rate for patients with advanced or metastatic gastrointestinal stromal tumor (GIST).